Background The benefi ts of blood pressure lowering treatment for prevention of cardiovascular disease are well established. However, the extent to which these eff ects diff er by baseline blood pressure, presence of comorbidities, or drug class is less clear. We therefore performed a systematic review and meta-analysis to clarify these diff erences.
Introduction
Elevated blood pressure is the most important risk factor for death and disability worldwide, aff ecting more than one billion individuals and causing an estimated 9·4 million deaths every year. 1 Prospective cohort studies have reported a continuous log-linear association between blood pressure and vascular events to a blood pressure of 115/75 mm Hg, with no apparent threshold. 2 This association seems to exist across large and diverse population groups, including men and women, individuals aged 40-89 years, from diff erent ethnicities, with and without established vascular disease. [2] [3] [4] Despite this robust observational evidence, whether blood pressure lowering treatment reduces the risk of cardiovascular disease in all patient populations remains unclear.
Although the benefi ts of blood pressure lowering have long been established in randomised trials of patients with substantially raised blood pressures, [5] [6] [7] [8] evidence for the protective eff ects of pharmacologically-induced blood pressure reduction in individuals with lower blood pressure or with comorbidities, have been less certain. [9] [10] [11] [12] Furthermore, the best approach to reduce blood pressure remains subject to controversy.
Recent major guidelines have reversed a trend toward lower blood pressure thresholds and targets, recommending higher targets and threshold for blood pressure lowering than have previous guidelines. 14, 17, 18 The SPRINT trial 12 reported the benefi ts of blood pressure lowering to 120 mm Hg in some high-risk groups of patients. However uncertainty remains as to whether such benefi ts hold for high-risk individuals excluded from the trial, especially those with diabetes or cerebrovascular disease. 12 In this systematic review and meta-analysis, we aimed to combine data from all published large-scale blood pressure lowering trials to quantify the eff ects of blood pressure reduction on cardiovascular outcomes and death across various baseline blood pressure levels, major comorbidities, and diff erent pharmacological interventions.
Methods

Search strategy and selection criteria
The systematic review and tabular meta-analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for metaanalyses of interventional studies. 19 We searched MEDLINE from Jan 1, 1966, to July 7, 2015 , using an existing search strategy 16 with the terms "antihypertensive agents" or "hypertension" or "diuretics", "thiazide", or "angiotensin-converting enzyme" or "angiotensin-converting enzyme inhibitors" or "receptors, angiotensin/antagonists & inhibitors" or "tetrazoles" or "calcium channel blockers" or "vasodilator agents" or the names of all blood pressure lowering drugs listed in the British National Formulary as keywords or text words or the MeSH term "blood pressure/drug eff ects". Search terms used in the MEDLINE search are provided in the appendix (pp [39] [40] [41] . We restricted our search to clinical trials, controlled clinical trials, randomised controlled trials, or meta-analyses. We applied no language restrictions. Reference lists of eligible studies and related metaanalyses were hand searched to identify further relevant studies.
All randomised controlled trials of blood pressure lowering treatment published between Jan 1, 1966 , and Nov 9, 2015, were eligible for inclusion. Eligible studies fell into three categories: fi rst, random allocation of participants to a blood pressure lowering drug or placebo; second, random allocation of participants to diff erent blood pressure lowering drugs; and third, random allocation of participants to diff erent blood pressure lowering targets. To minimise the risk of small-study eff ects, 20 all studies were required to have a minimum of 1000 patient-years of follow-up in each study group, the same criterion applied in the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC). 21 Trials of anti hypertensive drugs for indications other than hypertension were eligible. No trials were excluded because of the presence of baseline comorbidities.
Data analysis
Two researchers (DE and CAE) screened all abstracts identifi ed in the initial search and excluded studies in violation of the inclusion criteria. Full-text articles were subsequently reviewed in duplicate and, in cases of disagreement, consensus was achieved through referral See Online for appendix
Research in context
Evidence before this study Although the benefi ts of blood pressure lowering treatment for prevention of cardiovascular disease are well established, the extent to which these eff ects diff er by baseline blood pressure, presence of comorbidities, or drug class is less clear.
Added value of this study
Our study provides a comprehensive systematic review and meta-analysis of all available large-scale blood pressure lowering randomised trials. Our fi ndings show that pharmacological blood pressure lowering results in similar proportional reductions in risk of cardiovascular disease and death to a mean baseline systolic blood pressure of less than 130 mm Hg. Furthermore, we noted that proportional risk reductions are broadly similar among individuals with or without major cardiovascular comorbidities. Finally, our fi ndings emphasise the fact that, despite the general effi cacy of commonly prescribed blood pressure lowering drug classes in preventing cardiovascular disease, there are some signifi cant diff erences among them in the reduction of risk of specifi c clinical outcomes. For example, calcium channel blockers seem to be more eff ective than other classes of drugs for stroke prevention, and diuretics are more eff ective for prevention of heart failure.
Implications of all the available evidence
Our study has several implications for clinical practice. First, our fi ndings suggest that blood pressure lowering to levels below those recommended in current guidelines (ie, systolic blood pressure of less than 140 mm Hg) will reduce the risk of cardiovascular disease. Second, by showing no evidence for a threshold below which blood pressure lowering ceases to work, the fi ndings call for blood pressure lowering based on an individual's potential net benefi t from treatment rather than treatment of the risk factor to a specifi c target. Third, the broad consistency of the fi ndings across patients with or without prior vascular disease could help to simplify clinical guidelines for use of blood pressure lowering drugs. Fourth, the diff erences we identifi ed between classes of drugs support more targeted drug use for individuals at high risk of specifi c outcomes (eg, calcium channel blocker therapy for individuals at high risk of stroke).
to a third reviewer (KR). An electronic data abstraction form was used to record patient and study characteristics, including sample size, treatment comparisons, baseline blood pressure, blood pressure achieved, and mean blood pressure reduction. If not reported, corresponding authors were contacted to obtain data about baseline and achieved blood pressure by use of individually tailored data request forms.
Data were also extracted for major cardiovascular disease events (defi ned as fatal and non-fatal myocardial infarction, sudden cardiac death, revascularisation, fatal and non-fatal stroke, and fatal and non-fatal heart failure), coronary heart disease (fatal and non-fatal myocardial infarction and sudden cardiac death, excluding silent myocardial infarction), stroke (fatal and non-fatal, excluding transient ischaemic attacks), heart failure (new diagnosis of heart failure, hospital admission, or death), renal failure (end-stage renal disease resulting in dialysis, transplantation, or death), and all-cause mortality. Information was extracted about the number of patients in each group with the baseline comorbidities of cardiovascular disease, coronary heart disease, cerebrovascular accident (history of stroke or transient ischaemic attack), type 2 diabetes, heart failure, and chronic kidney disease (self-reported chronic kidney disease or creatinine clearance <30 mL/min). The SPRINT trial 12 reported renal failure for patients with chronic kidney disease at baseline; this was recorded for the entire trial.
For all outcomes, the number of events in each group and the summary statistic (either relative risk [RR] or hazard ratio [HR] and 95% CIs) were extracted. We used HRs preferentially to RRs because they incorporate timeto-event and allow for censoring. 22 When neither summary statistic was provided, we calculated RRs from the number of events and participants in each treatment group. Conversely, if the total number of events was missing, we estimated it using the summary statistic and its confi dence interval.
We used the Cochrane risk of bias tool to assess the methodological quality of the eligible trials. 23 Selection bias (randomisation and allocation concealment), performance bias (blinding of participants and investigators), detection bias (blinding of outcome adjudicators), attrition bias (diff erential loss to follow-up), and reporting bias (selective outcome reporting) were judged to be of low, unclear, or high risk for each trial. We then judged each trial as a whole to ascertain whether there was low, unclear, or high risk of bias, based on whether the level of bias in each of the defi ned domains could have led to material biases in the risk estimates. 
Statistical analysis
We calculated overall summary estimates and 95% CIs with inverse variance weighted fi xed-eff ects meta-analyses because heterogeneity was low 24 and random-eff ects meta-analysis might apply inappropriately large weights to smaller studies. 25 We characterised heterogeneity with the I² statistic. We used Cochran's Q statistic to test for subgroup interactions and χ² tests to test for trend in analyses stratifi ed by baseline systolic blood pressure. All p values were calculated from twotailed tests of statistical signifi cance with a type I error rate of 5%.
We did analyses to establish, fi rst, the eff ect of a 10 mm Hg blood pressure reduction on the relative risk of major cardiovascular disease, coronary heart disease, stroke, heart failure, renal failure, and all-cause mortality; second, the eff ect of a 10 mm Hg blood pressure reduction at diff erent baseline blood pressure levels by stratifi cation of trials into fi ve strata of reported mean baseline systolic blood pressure at the trial level (<130, 130-139, 140-149, 150-159, and ≥160 mm Hg); third, the eff ects of a 10 mm Hg blood pressure reduction on the relative risk of major cardiovascular disease, coronary heart disease, stroke, heart failure, renal failure, and all-cause mortality in the presence of baseline comorbidities (cardiovascular disease, coronary heart disease, cerebrovascular accident, type 2 diabetes, heart failure, and chronic kidney disease) by investigation of possible interactions in treatment eff ect by these comorbidities; and fourth, the eff ects of diff erent classes of blood pressure lowering drugs.
For the fi rst three objectives, we standardised the analyses to a 10 mm Hg reduction in systolic blood pressure because we were interested in the proportional eff ects of lowering systolic blood pressure by 10 mm Hg and because the trials varied in the relative intensity of blood pressure lowering achieved due to diff erences in strategies and drugs. We standardised the analyses by multiplying the log of the summary statistic of each trial (and its standard error) by 10/d, where d was the average systolic blood pressure reduction in that trial.
For example, if the logHR was -0·2 and the systolic blood pressure reduction was 4 mm Hg, the standardised logHR would be -0·2 × (10/4) = -0·5. We examined non-standardised eff ects of blood pressure lowering by baseline systolic blood pressure in sensitivity analyses.
We did meta-regression to assess the validity of the assumption that reductions in RR would be proportional to the achieved blood pressure reduction. The percentage reductions in proportional risk of major cardiovascular disease events, coronary heart disease, stroke, heart failure, renal failure, and all-cause mortality were regressed against the diff erence in mean achieved systolic blood pressure between the intervention and control groups.
Trials of blood pressure lowering drugs versus placebo or higher versus lower blood pressure targets were combined for the purposes of the fi rst three objectives. For the six trials with three arms, including two active groups and a placebo group 10, [26] [27] [28] [29] [30] [31] and the one trial that had four arms including a placebo group, 32 we combined the active groups for the blood pressure lowering analysis by combining the events and taking a weighted average of baseline blood pressure, achieved blood pressure, and blood pressure reduction.
For the fourth objective, the comparison of drug classes, we did not standardise the analyses in order to account for variations in blood pressure lowering effi cacy, tolerability, or non-blood pressure-mediated eff ects of the diff erent drug classes. In these analyses, we examined possible diff erences in the eff ects of blood pressure lowering by drug class by comparing trials that tested a specifi c class of drug (angiotensin-converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARB], β blockers, diuretics, and calcium channel blockers [CCB] ) against all other classes that it has been compared with. Because the pooled comparators might vary for each class (for example, β blockers might have mostly been tested against CCBs, whereas diuretics might have mostly been tested against ACE inhibitors), we also did an analysis in which we compared each individual drug class to all of the individual classes it has been tested against. 
Favours control Favours intervention
We excluded trials that were done in populations with heart failure or left ventricular systolic dysfunction from all of the main standardised analyses, because the eff ects of antihypertensive use on achieved blood pressure in heart failure have been reported to vary substantially with baseline blood pressure within the same trial population (thus rendering mean achieved blood pressure less meaningful). [33] [34] [35] Furthermore, only a few heart failure trials have actually reported mean achieved blood pressure by treatment allocation. However, we did complementary sensitivity analyses that included heart failure trials (both standardised and non-standardised) with the available information from published reports. 
We did all analyses with Stata version 13.1 and R version 3.2.0.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. KR and DE had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
In total, we screened 11 428 abstracts, of which 350 were eligible for full-text review (fi gure 1). Of the 134 randomised controlled trials identifi ed, 123 trials with 613 815 participants were eligible for inclusion in the metaanalysis. 92 studies were deemed to be trials of blood pressure lowering because they compared either blood pressure lowering drugs to placebo (78 trials) or diff erent blood pressure lowering targets (14 trials; appendix pp 1-6, 10). 43 trials compared diff erent drug classes and were included in the drug comparison analysis (appendix pp 1-10). 12 trials fell into both categories, with fi ve trials assessing diff erent blood pressure lowering targets and drug classes [36] [37] [38] [39] [40] [41] [42] and seven trials comparing blood pressure lowering drugs to placebo and diff erent drug classes. 26, [28] [29] [30] 32, 43, 44 Ten studies were judged to be of unclear risk of bias and 113 were deemed to be at low risk of bias. [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] Heterogeneity for outcomes was low to moderate; the I² statistic for heterogeneity for major cardiovascular disease events was 41%, for coronary heart disease 25%, for stroke 26%, for heart failure 37%, for renal failure 28%, and for all-cause mortality 35%. The appendix shows details of the methods of blood pressure measurement for the included trials (appendix pp [11] [12] [13] [14] .
Meta-regression analyses showed relative risk reductions for major cardiovascular disease events (p<0·0001), stroke (p<0·0001), heart failure (p<0·0001), and all-cause mortality (p=0·014) to be proportional to the magnitude of the blood pressure reduction achieved (fi gure 2, appendix pp 15-16). The meta-regression results were not signifi cant for coronary heart disease (p=0·058) or renal failure (p=0·09; appendix pp [16] [17] .
Every 10 mm Hg systolic blood pressure reduction signifi cantly reduced the risk of major cardiovascular disease events (RR 0·80, 95% CI 0·77-0·83), coronary heart disease (0·83, 0·78-0·88), stroke (0·73, 0·68-0·77), heart failure (0·72, 0·67-0·78), and all-cause mortality (0·87, 0·84-0·91; fi gure 3, appendix pp 18-23). The proportional reductions per 10 mm Hg systolic blood pressure reduction were greater for stroke and heart failure than for coronary heart disease. Estimates in nonstandardised analyses were consistent with standardised estimates (appendix p 24).
When we stratifi ed trials by mean baseline systolic blood pressure and compared the eff ects of a 10 mm Hg reduction in systolic blood pressure between strata, we detected no signifi cant trends for any outcomes (p trend >0·05; fi gure 4). Estimates were similar for nonstandardised analysis (appendix p 25) .
No evidence of diff erent proportional eff ects of blood pressure lowering existed when we stratifi ed trials by baseline cardiovascular disease (all p interaction >0·05; fi gure 5) and, in view of the multiplicity of tests done (which increases the likelihood of observing a chance fi nding when considering all tests), no strong evidence of diff erences existed when trials were stratifi ed by baseline coronary heart disease (all p interaction >0·03; appendix p 26). Although there was some evidence to suggest that the eff ect of blood pressure lowering on stroke was modifi ed by presence of baseline coronary heart disease (p=0.03), we cannot rule out that this weak evidence is entirely due to chance given the multiplicity of testing. However, the proportional reduction in stroke risk seemed to be larger in populations without a history of cerebrovascular disease than in populations with such a history (p interaction =0·0028; appendix p 27). When we stratifi ed trials by baseline diabetes, we detected a signifi cant interaction (p=0·0006) for major cardiovascular disease events, with signifi cantly larger risk reductions for populations without diabetes (RR 0·75, 95% CI 0·70-0·80) than in populations with diabetes (0·88, 0·82-0·94; appendix p 28). Our subgroup analysis based on the presence of heart failure suggested that a 10 mm Hg blood pressure reduction might increase the risk of renal failure in patients with heart failure (21·67, 3·75-125·21), but this result was based on just 84 renal failure events in two studies (appendix pp 29-30). When we stratifi ed trials by baseline chronic kidney disease, a signifi cant interaction existed for major cardiovascular disease events (p interaction =0·012), with larger proportional risk reductions for the populations without chronic kidney disease (0·68, 0·62-0·75) than in the populations with chronic kidney disease (0·84, 0·73-0·96). A signifi cant interaction also existed for heart failure events, with a large and statistically signifi cant risk reduction of 52% (0·48, 0·38-0·62) for every 10 mm Hg systolic blood pressure reduction in the subgroup without chronic kidney disease compared with a non-signifi cant reduction for the subgroup with chronic kidney disease (0·95, 0·70-1·29; p interaction =0·0008; appendix p 31).
We examined the fi ve classes of blood pressure lowering drugs in non-standardised analyses. The diff erent drug classes were of largely similar eff ectiveness for prevention of the various outcomes (fi gure 6, appendix pp 32-37). However, β blockers were less effi cacious than other medications for the prevention of major cardiovascular disease events (RR 1·17, 95% CI 1·11-1·24; fi gure 6, appendix p 32), stroke (1·24, 1·14-1·35; fi gure 6, appendix p 33), and renal failure (1·19, 1·05-1·34; fi gure 6, appendix p 34). Evidence also suggested that β blockers had inferior effi cacy in the prevention of all-cause mortality (1·06, 1·01-1·12; fi gure 6, appendix p 35), although this diff erence was not signifi cant. CCBs were superior to the other classes for stroke prevention (0·90, 0·85-0·95; fi gure 6, appendix p 33) but were inferior to the other classes for heart failure prevention (1·17, 1·11-1·24; fi gure 6, appendix p 37). Diuretics were superior to other classes for heart failure prevention (0·81, 0·75-0·88; fi gure 6, appendix p 37). Results were similar when heart failure trials were included in the analysis (appendix p 38).
Discussion
In this meta-analysis, blood pressure lowering treatment signifi cantly reduced the risk of cardiovascular disease and death in various populations of patients. Overall, a 10 mm Hg reduction in systolic blood pressure reduced the risk of major cardiovascular disease events by 20%, coronary heart disease by 17%, stroke by 27%, heart failure by 28%, and all-cause mortality by 13%. The size of these proportional reductions was broadly consistent across several major high-risk groups of patients, suggesting that blood pressure lowering provides broadly generalisable benefi ts. In stratifi ed analyses, we saw no strong evidence that proportional eff ects were diminished in trials that included people with lower baseline systolic blood pressure (<130 mm Hg), and major cardiovascular events were clearly reduced in high-risk patients with various baseline comorbidities. Both of these major fi ndings-the effi cacy of blood pressure lowering below 130 mm Hg and the similar proportional eff ects in highrisk populations-are consistent with and extend the fi ndings of the SPRINT trial. 12 Collectively, these data suggest that revision is urgently needed to recent blood pressure lowering guidelines that have relaxed the blood pressure lowering thresholds. 14, 17, 18 Our fi nding of a lack of overall benefi t of blood pressure lowering for renal failure events is consistent with those of a previous meta-analysis 56 that assessed the eff ects of intensive versus moderate blood pressure reduction on the risk of end-stage kidney disease. Blood pressure lowering seems to have multiple and sometimes opposing eff ects on renal outcomes: long-term blood pressure lowering reduces proteinuria and other indicators of structural damage, especially but not exclusively when achieved by renin-angiotensin-aldosterone (RAAS) inhibitors, but increases in acute kidney injury have also been reported. 12, 57 These eff ects might be because of the fact that renal failure is not a single disorder, but a group of diseases with diff erent underlying pathological mechanisms, with both high and low blood pressure contributing to its clinical manifestation.
A key insight from our analysis is that the eff ects of blood pressure lowering were broadly similar by baseline comorbidity. The proportional reduction in major cardiovascular disease events from blood pressure lowering did not diff er substantially with the presence or absence of previous cardiovascular disease events, coronary heart disease, or cerebrovascular disease at the time of trial inclusion. With such consistent relative eff ects, we expect that the absolute benefi ts of blood pressure lowering would be greatest among individuals at highest absolute risk of cardiovascular events. 56, 58 However, we did note some diff erences if diabetes or chronic kidney disease were present at baseline. The proportional reduction in major cardiovascular disease events seemed to be larger in trials done in people without diabetes or chronic kidney disease. The cause of these diff ering proportional reductions is unclear. One possibility is that the trials done in people with diabetes or chronic kidney disease diff ered in their methodological characteristics, such as length of follow-up or use of dual reninangiotensin system inhibition. 59 Another possibility is that the non-signifi cant fi nding of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, which was weighted heavily in the diabetic subgroup analysis, might have been caused by chance. 57 Another key fi nding from our analysis was that, although diff erent drug classes were of largely similar eff ectiveness for prevention of the vascular outcomes of interest, there was evidence of modest diff erential eff ects between drug classes. β blockers seemed to be inferior to other classes of blood pressure lowering drugs for the prevention of major cardiovascular disease events, stroke, renal failure, and allcause mortality, whereas CCBs seemed to be inferior and diuretics superior for the prevention of heart failure to other classes. 18, 60, 61 In line with previous research and current recommendations, CCBs seemed to be superior to other drug classes for stroke prevention.
14,16,60 Although we detected small but signifi cant diff erences between the eff ectiveness of particular classes for other outcomes, we cannot exclude the possibility that these eff ects might have arisen from diff erences in the control regimens, or by chance in view of the multiple comparisons done. Additionally, apparent diff erences between drug classes might have been modifi ed by the concurrent use of multiple classes of blood pressure lowering drugs in many trials. For example, the ACE inhibitor and CCB combination has been investigated in a large trial 62 and was reported to be more eff ective for prevention of major cardiovascular disease than was an ACE inhibitor and diuretic combination. Finally, certain drug classes might have particularly strong positive or negative eff ects in specifi c patient subgroups (eg, β blockers in the fi rst years after a myocardial infarction 16 ); an eff ect that we did not investigate in this review of the totality of evidence across diff erent populations. Individual patient data metaanalyses of the type done by the BPLTTC might be able to address these questions in the future.
The broad consistency of the proportional eff ects of blood pressure lowering on cardiovascular outcomes across various baseline blood pressure levels and several disease categories will challenge the current guidelines on blood pressure and will support the case to shift their focus from rigid blood pressure targets to risk-based targets, even when starting systolic blood pressure is lower than 130 mm Hg. 63 Rather than a decision based on an arbitrary threshold for a single risk factor, this approach needs individualised assessment of the balance of absolute risks and benefi ts when physicians decide on the blood pressure level at which to start blood pressure lowering and the target blood pressure. 64 For this meta-analysis, adverse event data were too disparate and inconsistently reported to allow for formal analysis. However, our analysis did provide evidence against blood pressure lowering causing an increase in major cardiovascular events in patients with previous disease and low baseline blood pressure, which was a concern raised by reports of J-curve associations.
Pooling data from 613 815 patients enrolled in 123 largescale trials of blood pressure lowering, our study includes substantially more information than any previous metaanalyses that have addressed this question. Unlike in previous studies, we excluded no trials because of baseline comorbidities, thus allowing for greater generalisability of fi ndings and an assessment of treatment eff ect stratifi ed by the presence of various baseline comorbidities of interest. 65, 66 With ageing populations, chronic kidney disease is becoming an increasingly prevalent and important public health problem, aff ecting 10-15% of the adult population. [67] [68] [69] [70] Our fi ndings show signifi cant relative risk reductions for both patients with and patients without chronic kidney disease. Although proportional risk reductions were smaller in patients with chronic kidney disease than in those without, in view of their higher absolute risks, substantial absolute benefi ts from blood pressure reduction can be achieved in this population.
A limitation of this meta-analysis is that we had no individual patient data, the use of which would have provided greater detail about the eff ects of blood pressure lowering at various levels of baseline systolic blood pressure. However, the eligible trials spanned a wide range of baseline blood pressure levels, allowing us to explore the eff ects of blood pressure lowering across a relatively wide range of blood pressures. A further limitation was that the eligible trials varied in several respects, including diff erences in trial populations, baseline comorbidities, and treatment regimens, and it is possible that methodological diff erences might have confounded the diff erences recorded across subgroups of trials. Although many studies have investigated diff erences in the clinical effi cacy of various drug classes for cause-specifi c outcomes, relatively few studies have compared diff erent drug combinations. Because most patients need combination therapy, identifi cation of the optimum combinations of therapies might be more clinically relevant than investigating the eff ectiveness of single therapies. The fact that we had no individual patient data prevented such an analysis.
In conclusion, blood pressure lowering signifi cantly reduces the risk of major cardiovascular disease events, coronary heart disease, stroke, heart failure, and all-cause mortality, with similar proportional reductions across various population subgroups, irrespective of starting blood pressure. Lowering of blood pressure into what has been regarded the normotensive range should therefore be routinely considered for the prevention of cardiovascular disease among those deemed to be of suffi cient absolute risk.
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